Thrombocytopenia in the intensive care unit-diagnostic approach and management

Seminars in Hematology

Volumn 50, Issue 3, 2013, Pages 239-250

  Thiele, Thomas ^a   Selleng, Kathleen ^a   Selleng, Sixten ^a   Greinacher, Andreas ^a   Bakchoul, Tamam ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN;

ALCOHOL INTOXICATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CRITICALLY ILL PATIENT; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDUCED DISEASE; DRUG INTOXICATION; DRUG SAFETY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOPATHOGENESIS; INTENSIVE CARE UNIT; MORTALITY; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PURPURA; RISK FACTOR; SEPSIS; SURGICAL PATIENT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERAPY EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE INJURY;

CRITICAL ILLNESS; HEMORRHAGE; HUMANS; INTENSIVE CARE UNITS; PLATELET COUNT; PLATELET TRANSFUSION; POSTOPERATIVE COMPLICATIONS; THROMBOCYTOPENIA;

EID: 84881599440     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.06.008     Document Type: Article

References (80)

1. Hui P., Cook D.J., Lim W., Fraser G.A., Arnold D.M. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest 2011, 139(2):271-278.
2. Crowther M.A., Cook D.J., Meade M.O., et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005, 20(4):348-353.
3. Drews R.E. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003, 24(4):607-622.
4. Vanderschueren S., De Weerdt A., Malbrain M., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28(6):1871-1876.
5. Strauss R., Wehler M., Mehler K., et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30(8):1765-1771.
6. Thrombocytopenia and thrombocytosis 2007, 983-1005. Informa Healthcare, New York.
7. Rice T.W., Wheeler A.P. Coagulopathy in critically ill patients: part 1: platelet disorders. Chest 2009, 136(6):1622-1630.
8. Stanworth S.J., Walsh T.S., Prescott R.J., et al. Intensive Care Study of Coagulopathy Investigators. Thrombocytopenia and platelet transfusion in UK critical care: a multicenter observational study. Transfusion 2013, 5(5):1050-1058.
9. Crowther M.A., Cook D.J., Albert M., et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010, 25(2):287-293.
10. Bain B.J. Diagnosis from the blood smear. N Engl J Med 2005, 353(5):498-507.
11. Sane D.C., Damaraju L.V., Topol E.J., et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000, 36(1):75-83.
12. Lippi G., Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med 2012, 50(8):1281-1285.
13. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332(20):1330-1335.
14. Pouplard C., May M.A., Iochmann S., et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999, 99(19):2530-2536.
15. Selleng S., Malowsky B., Strobel U., et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 2010, 8(1):30-36.
16. Nijsten M.W., ten Duis H.J., Zijlstra J.G., et al. Blunted rise in platelet count in critically ill patients is associated with worse outcome. Crit Care Med 2000, 28(12):3843-3846.
17. Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program 2009, 147-152.
18. Wang B., Nichol J.L., Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004, 76(6):628-638.
19. Stansbury L.G., Hess A.S., Thompson K., et al. The clinical significance of platelet counts in the first 24 hours after severe injury. Transfusion 2013, 5(4):783-789.
20. Lubenow N., Hinz P., Thomaschewski S., et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010, 115(9):1797-1803.
21. Floccard B., Rugeri L., Faure A., et al. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury 2012, 43(1):26-32.
22. Brown L.M., Call M.S., Margaret Knudson M., et al. A normal platelet count may not be enough: the impact of admission platelet count on mortality and transfusion in severely injured trauma patients. J Trauma 2011, 71(2 Suppl 3). S337-42.
23. Kasirajan V., Smedira N.G., McCarthy J.F., et al. Risk factors for intracranial hemorrhage in adults on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 1999, 15(4):508-514.
24. Akca S., Haji-Michael P., de Mendonca A., et al. Time course of platelet counts in critically ill patients. Crit Care Med 2002, 30(4):753-756.
25. Vandijck D.M., Blot S.I., De Waele J.J., et al. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung 2010, 39(1):21-26.
26. Moreau D., Timsit J.F., Vesin A., et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest 2007, 131(6):1735-1741.
27. Greinacher A., Kiefel V., Kluter H., et al. [Recommendations for platelet transfusion by the Joint Thrombocyte Working Party of the German Societies of Transfusion Medicine and Immunohaematology (DGTI), Thrombosis and Haemostasis Research (GTH), and Haematology and Oncology (DGHO)]. Dtsch Med Wochenschr 2006, 131(47):2675-2679.
28. Stainsby D., MacLennan S., Hamilton P.J. Management of massive blood loss: a template guideline. Br J Anaesth 2000, 85(3):487-491.
29. Valeri C.R., Cassidy G., Pivacek L.E., et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001, 41(8):977-983.
30. Vamvakas E.C., Blajchman M.A. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009, 113(15):3406-3417.
31. Cook D.J., Crowther M.A., Meade M.O., Douketis J. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005, 20(4):309-313.
32. Ben Hamida C., Lauzet J.Y., Rezaiguia-Delclaux S., et al. Effect of severe thrombocytopenia on patient outcome after liver transplantation. Intensive Care Med 2003, 29(5):756-762.
33. Shalansky S.J., Verma A.K., Levine M., Spinelli J.J., Dodek P.M. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy 2002, 22(7):803-813.
34. Chakraverty R., Davidson S., Peggs K., et al. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996, 93(2):460-463.
35. Bilgin Y.M., van de Watering L.M., Versteegh M.I., et al. Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion 2011, 51(12):2603-2610.
36. Wandt H., Schaefer-Eckart K., Wendelin K., et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012, 380(9850):1309-1316.
37. Slichter S.J., Kaufman R.M., Assmann S.F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362(7):600-613.
38. Li C., Hirsh J., Xie C., Johnston M.A., Eikelboom J.W. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 2012, 10(4):521-528.
39. Thiele T., Sumnig A., Hron G., et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost 2012, 10(5):968-971.
40. Brown J.B., Cohen M.J., Minei J.P., et al. Debunking the survival bias myth: characterization of mortality during the initial 24 hours for patients requiring massive transfusion. J Trauma Acute Care Surg 2012, 73(2):358-364.
41. Kutcher M.E., Redick B.J., McCreery R.C., et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 2012, 73(1):13-19.
42. Shakur H., Roberts I., Bautista R., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010, 376(9734):23-32.
43. Takemitsu T., Wada H., Hatada T., et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011, 105(1):40-44.
44. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009, 145(1):24-33.
45. Kitchens C.S. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematology Am Soc Hematol Educ Program 2009, 240-246.
46. Lee K.H., Hui K.P., Tan W.C. Thrombocytopenia in sepsis: a predictor of mortality in the intensive care unit. Singapore Med J 1993, 34(3):245-246.
47. Martin C.M., Priestap F., Fisher H., et al. A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry. Crit Care Med 2009, 37(1):81-88.
48. Sharma B., Sharma M., Majumder M., et al. Thrombocytopenia in septic shock patients-a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care 2007, 35(6):874-880.
49. Greinacher A., Warkentin T.E. Acquired non-immune thrombocytopenia. Hemostasis and thrombosis: basic principles and clinical practice. Ed 6 2013, 1292-1307. Lippincott Williams & Wilkins, Philadelphia. V.J. Marder, W.C. Aird, J.S. Bennett (Eds.).
50. Afdhal N., McHutchison J., Brown R., et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008, 48(6):1000-1007.
51. Fischereder M., Jaffe J.P. Thrombocytopenia following acute acetaminophen overdose. Am J Hematol 1994, 45(3):258-259.
52. Blackburn S.C., Oliart A.D., Garcia Rodriguez L.A., Perez Gutthann S. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998, 18(6):1277-1283.
53. Isbister G.K. Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost 2010, 36(4):444-451.
54. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339(22):1578-1584.
55. Sadler J.E. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008, 112(1):11-18.
56. Naqvi T.A., Baumann M.A., Chang J.C. Post-operative thrombotic thrombocytopenic purpura: a review. Int J Clin Pract 2004, 58(2):169-172.
57. George J.N., Al-Nouri Z.L. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program 2012, 2012:604-609.
58. Noris M., Mescia F., Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012, 8(11):622-633.
59. Gruppo R.A., Rother R.P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360(5):544-546.
60. Kielstein J.T., Beutel G., Fleig S., et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012, 27(10):3807-3815.
61. Greinacher A., Friesecke S., Abel P., et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011, 378(9797):1166-1173.
62. Asherson R.A., Cervera R., de Groot P.G., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12(7):530-534.
63. Espinosa G., Berman H., Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011, 10(11):664-668.
64. Lonze B.E., Singer A.L., Montgomery R.A. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010, 362(18):1744-1745.
65. Smith K.M., Jeske C.S., Young B., Hatton J. Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients. Neurosurgery 2006, 58(3):426-433.
66. George J.N., Aster R.H. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 2009, 153-158.
67. Arnold D.M., Kukaswadia S., Nazi I., et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost 2013, 11(1):169-176.
68. Williamson L.M., Stainsby D., Jones H., et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 2007, 47(8):1455-1467.
69. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001, 344(17):1286-1292.
70. Trehel-Tursis V., Louvain-Quintard V., Zarrouki Y., et al. Clinical and biological features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. Chest 2012, 142(4):837-844.
71. Cook D., Meade M., Guyatt G., et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011, 364(14):1305-1314.
72. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4(4):759-765.
73. Cuker A., Gimotty P.A., Crowther M.A., Warkentin T.E. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012, 120(20):4160-4167.
74. Cuker A., Arepally G., Crowther M.A., et al. The HIT Expert Probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010, 8(12):2642-2650.
75. Messmore H.L., Fabbrini N., Bird M.L., et al. Simple scoring system for early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2011, 17(2):197-201.
76. Bakchoul T., Giptner A., Najaoui A., et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009, 7(8):1260-1265.
77. Greinacher A., Michels I., Kiefel V., Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991, 66(6):734-736.
78. Selleng K., Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007, 35(4):1165-1176.
79. Selleng S., Selleng K., Wollert H.G., et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 2008, 6(3):428-435.
80. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives 4th ed. Transfusion Med Hemother. 2009;36(6).